<DOC>
	<DOC>NCT02478008</DOC>
	<brief_summary>The purpose of the study is to evaluate the initial short and long-term safety and performance of the CardiAQ™ Transcatheter Mitral Valve Implantation System using the Transapical Delivery System. The study will enroll patients with moderate to severe mitral valve regurgitation who are considered high or extreme risk for mortality and morbidity from conventional open heart surgery.</brief_summary>
	<brief_title>A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key NYHA Classification ≥ III Left Ventricular Ejection Fraction ≥ 30% Mitral regurgitation ≥ Grade 3+ Subject meets anatomical eligibility criteria for the investigational device</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Transcatheter Mitral Valve Replacement</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Transapical</keyword>
</DOC>